Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Appointed director
RELMADA THERAPEUTICS, INC. (RLMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
10/10/2023 8-K Quarterly results
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED OCTOBER 4, 2023"
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED AUGUST 10, 2023"
08/08/2023 8-K Quarterly results
Docs: "Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets As of June 30, 2023"
05/25/2023 8-K Appointed a new director
Docs: "RELMADA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN, AS AMENDED"
05/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED MAY 15, 2023"
05/11/2023 8-K Quarterly results
Docs: "Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets As of As of March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 28,894,360 $ 5,395,905 Short-term investments 103,547,634 142,926,781 Other receivables - 512,432 Prepaid expenses 3,089,580 4,035,186 Total current assets 135,531,574 152,870,304 Other assets 34,875 34,875 Total assets $ 135,566,449 $ 152,905,179 Commitments and Contingencies Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 4,421,965 $ 5,261,936 Accrued expenses 5,675,292 7,206,941 Total current liabilities 10,097,257 12,468,877 Total liabilities 10,097,257 12,468,877 Stockholders’ Equity: Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding - -..."
04/19/2023 8-K Quarterly results
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results CORAL GABLES, Fla., Mar 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022. The Company will host a conference call today, Thursday, March 23, at 4:30 PM Eastern Time/1:30 PM Pacific Time. “Following the availability of top-line results in the Reliance I , one of two Phase 3 sister two-arm, placebo-controlled, pivotal studies evaluating REL-1017 25mg as a potential adjunctive treatment for major depressive disorder , in December 2022, we have..."
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
01/09/2023 8-K Quarterly results
01/05/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics, Inc"
12/28/2022 8-K Quarterly results
12/07/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/13/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder"
09/22/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION",
"FORM OF EXCHANGE WARRANT",
"Letter re: Section 3 Exchange Agreement"
09/20/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics Announces Completion of Treatment in Company’ s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder"
06/01/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/23/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics, Inc. Consolidated Balance Sheets As of As of December 31, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 44,443,439 $ 2,495,397 Short-term investments 167,466,167 114,595,525 Lease payments receivable – short term 86,377 79,457 Prepaid expenses 11,301,535 903,190 Total current assets 223,297,518 118,073,569 Fixed assets, net of accumulated depreciation - 1,258 Other assets 28,293 25,000 Lease payments receivable – long term - 86,377 Total assets $ 223,325,811 $ 118,186,204 Commitments and Contingencies Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 11,192,502 $ 8,346,475 Accrued expenses 3,868,423 4,256,983 Total current liabilities 15,060,925 12,603,458 Total liabilities 15,060,925 12,603,458 Stockholders’ Equi..."
03/07/2022 8-K Quarterly results
02/23/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential",
"SLIDE PRESENTATION: HUMAN ABUSE POTENTIAL (HAP) STUDY OF REL-1017 VS. KETAMINE",
"CORPORATE PRESENTATION DATED FEBRUARY 23, 2022"
12/22/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry - Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD -"
12/20/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED DECEMBER 20, 2021"
12/13/2021 8-K Quarterly results
12/07/2021 8-K Quarterly results
11/23/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED NOVEMBER 23, 2021"
11/15/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED NOVEMBER 2021"
10/07/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Media Inquiries:",
"CORPORATE PRESENTATION"
07/20/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy